Phase 2 Study of Adebrelimab Combined With Capecitabine as Post-Surgery Treatment for High-Risk Cholangiocarcinoma
Led by The First Affiliated Hospital with Nanjing Medical University · Updated on 2025-01-16
122
Participants Needed
4
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Cholangiocarcinoma is a cancer that originates in the bile ducts, and its main treatment is surgical removal of the tumor. Despite advances in imaging and surgical techniques, the rate of successful surgery and long-term survival remain low due to high recurrence after surgery. This trial investigates whether adding the drug Adebrelimab combined with capecitabine as a postoperative treatment can improve outcomes in patients with high-risk resected cholangiocarcinoma.
Participants will be randomly assigned to one of two groups one receiving Adebrelimab plus capecitabine and the other receiving capecitabine alone. Adebrelimab is given intravenously every three weeks at a dose of 1200 mg for one year. Capecitabine is taken orally twice daily on days 1 to 14 of a 21-day cycle for 6 to 8 cycles. This study is open-label and multicenter, focusing on comparing the safety and effectiveness of these treatment approaches after surgery.
During the study, participants will undergo regular assessments including imaging to check for tumor recurrence, laboratory tests, and monitoring for side effects. The primary goal is to measure the rate of recurrence-free survival one year after treatment begins. Secondary outcomes include overall survival over three years, recurrence-free survival over two years, and minimal residual disease monitoring. The total study duration includes all treatment cycles and follow-up assessments up to three years to evaluate long-term effects and safety.
CONDITIONS
Brief Title
Phase 2 Trial of Adjuvant Adebrelimab Combined With Capecitabine in High-Risk Resected Cholangiocarcinoma: ACHIEVE
Research Team
X
Xiangcheng Li, Prof. M.D.
C
Changxian Li, Prof. M.D.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
The First Affiliated Hospital with Nanjing Medical University
Lead Sponsor
Jinling Hospital, China
Collaborating Sponsor
Who Can Participate
Age: 18Years - 75Years
All Genders
Eligibility Criteria
You may qualify if you...
Signed informed consent form
Age between 18 and 75 years, any gender
ECOG performance status score of 0 or 1
Histologically confirmed cholangiocarcinoma (including intrahepatic and hilar types) with R0 resection and high-risk recurrence factors
No evidence of recurrence or metastasis on imaging within 28 days before randomization
No prior systemic anti-cancer treatment before surgery
Laboratory test results within 7 days before first treatment meeting specified blood count and biochemical criteria
Life expectancy greater than 6 months
You will not qualify if you...
Mixed hepatocellular carcinoma or non-biliary tract malignancies
Previous systemic cancer treatment
Other active or recent malignancies except certain treated skin, cervical, or thyroid cancers
Active tuberculosis infection within 1 year or untreated history of tuberculosis
Autoimmune diseases or immunodeficiency
Need for high-dose systemic corticosteroids or immunosuppressants
Severe heart, lung, or kidney dysfunction
Uncontrolled high blood pressure
Recent significant bleeding or coagulation disorders
Active hepatitis B or C infection
Active infections requiring treatment
HIV positive
History of psychiatric medication abuse, alcoholism, or drug addiction
Allergy to study medications
Other conditions affecting safety or trial compliance as judged by investigators
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Up to 1 year for Adebrelimab and capecitabine; 6 to 8 cycles (approximately 18 to 24 weeks) for capecitabine alone
Participants receive adjuvant therapy with either Adebrelimab combined with capecitabine or capecitabine alone after surgery to reduce the risk of cancer recurrence.
Visits every 3 weeks during treatment cycles
Follow-up
Duration - Up to 2 years
Participants are monitored for recurrence-free survival, overall survival, and safety after completing treatment.
Regular visits for assessments during the follow-up period
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Phase II Study of Adebrelimab with XELOX Chemotherapy Before and After Surgery for Locally Advanced Resectable Gastric and Gastroesophageal Junction Cancer
Non-Invasive PET Imaging Targeting CLDN18.2 for Detecting and Evaluating Gastric, Pancreatic, Bile Duct, and Esophageal Cancers
Detailed Study of Biliary Strictures and Focal Lesions in Liver, Pancreas, and Biliary Tract to Develop New Diagnostic and Treatment Technologies for Hepato-Pancreato-Biliary Cancers
Observational Study on Intra-Arterial Therapies for Primary Liver Cancer Including Hepatocellular and Cholangiocarcinoma
Phase 2 Study of Adebrelimab Combined With Capecitabine as Post-Surgery Treatment for High-Risk Cholangiocarcinoma
Study of Adebrelimab with Decitabine, Albumin-bound Paclitaxel, and Gemcitabine for First Treatment of Metastatic Pancreatic Cancer
Prospective Study of Robotic Major Liver Surgery with Biliary Reconstruction for Perihilar Cholangiocarcinoma
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Adebrelimab plus capecitabine versus capecitabine monotherapy for adjuvant treatment of high-risk resected cholangiocarcinoma (ACHIEVE): protocol for a phase II, multicentre, randomised controlled trial.